Omalizumab está aprovado como terapêutica de terceira linha em doentes a partir dos 12 anos de idade com urticária crónica espontânea refratária a anti-histamínicos. É apresentado o caso de um rapaz de oito anos de idade com história de lesões cutâneas maculopapulares migratórias, artralgias e hiperemia conjuntival. Os resultados analíticos não demonstraram alterações relevantes e a biópsia cutânea fo...
Introduction: Fever of unknown origin (FUO) remains a major diagnostic challenge, despite advances in the medical field. It can be caused by a broad spectrum of diseases with very different prognostic outcomes. Constant re-evaluation of clinical data is essential considering the dynamic changes in disease patterns. We aim to understand which clinical approach is most commonly used and recognize our local epidem...
N/a.; N/a.
The development of vaccines to prevent COVID-19 breakouts came with highly positive results but some unexpected side effects. Rare side effects have been seen with the BNT162b2 SARS-CoV 2 vaccine. Case Presentation: We present the case of a 45-year-old female patient who developed an acute kidney injury needing urgent hemodialysis one week after the second administration of the BNT162b2 SARS-CoV 2 vaccine. She ...
Background: Chronic urticaria (CU) is defined as recurrent urticaria lasting for more than 6 weeks. Objectives: We aimed to characterize the phenotypes of patients with CU refractory to standard dose anti-H1 antihistamine treatment and search for clinical predictors of poor disease control. Methods: Retrospective collection of data regarding clinical characteristics, comorbidities, treatment, and disease contro...